suppressing calcineurin phosphatase required for IL-2 synthesis. 8 It also inhibits the release of other inflammatory cytokines, including the ones secreted by various antigen-presenting cells, mast cells, and cells involved in the inflammatory cascade. 9 Therefore, it has been shown to be beneficial in patients of Parthenium dermatitis. In our study, a rapid response to dermatitis with disease remission was achieved in all the patients with ciclosporin and there were no clinical or biochemical adverse effects. Thus, ciclosporin appears to be an effective drug in treatment of patients with Parthenium dermatitis, particularly when corticosteroids and azathioprine are contraindicated. However, further controlled trials with a larger sample size are required to establish its effectiveness and safety in these patients.